Carfilzomib (PR-171)

製品コードS2853

Carfilzomib (PR-171)化学構造

分子量(MW):719.91

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

サイズ 価格(税別)  
JPY 79016.00
JPY 28220.00
JPY 44820.00
JPY 111220.00
JPY 144420.00

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.
ターゲット
Proteasome [1]
(ANBL-6 cells)
5 nM
体外試験

Carfilzomib inhibits proliferation in a variety of cell lines and patient-derived neoplastic cells, including multiple myeloma, and induced intrinsic and extrinsic apoptotic signaling pathways and activation of c-Jun-N-terminal kinase (JNK). Carfilzomib reveals enhanced anti-MM activity compared with bortezomib, overcome resistance to bortezomib and other agents, and acts synergistically with dexamethasone (Dex). Carfilzomib shoes preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM. Short exposure to low-dose Carfilzomib leads to preferential binding specificity for the β5 constitutive 20S proteasome and the β5i immunoproteasome subunits. Measurement of caspase activity in ANBL-6 cells pulsed with Carfilzomib reveals substantial increases in caspase-8, caspase-9, and caspase-3 activity after 8 hours, giving a 3.2-, 3.9- and 6.9-fold increase, respectively, over control cells after 8 hours. In carfilzomib pulse-treated cells, the mitochondrial membrane integrity is decreased to 41% (Q1 + Q2), compared with 75% in vehicle-treated control cells. [1] In another study, Carfilzomib has also shown preclinical effectiveness against hematological and solid malignancies. [2] Carfilzomib directly inhibits osteoclasts formation and bone resorption. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MM.1S NYDO[|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:xS|UxNTFyMDDuUS=> MVK0PEBp MlnDTWM2OMLiPdMgNVAhdk1? M3PEc|I2OzF{NUSz
NCI-H929  NFrzZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHIPWkxNTFyMDDuUS=> M{LuZ|Q5KGh? NVjIUmV[UUN3MDC9xsAyPCCwTR?= Mor0NlU{OTJ3NEO=
SUDHL16  NY[zdmE3SXCxcITvd4l{KEG|c4PhfS=> M3[5dFIvPeLCk{OuOUBvVQ>? NXjmb2lsPDhiaB?= MoS1[Y5p[W6lZYOgeIhmKGOnbHyg[IVifGhiY3:teJJm[XSvZX70JJdqfGhiQVPZNVIyPQ>? M{\WU|I2OjN7OUO1
SUDHL14 MlTKRZBweHSxc3nzJGF{e3OjeR?= NWDZcI5IOi534pETN{42KG6P M2ftc|Q5KGh? NIP0dopmdmijbnPld{B1cGViY3XscEBl\WG2aDDjc{11emWjdH3lcpQhf2m2aDDBR3kyOjF3 MV2yOVI{QTl|NR?=
U2932 MUDBdI9xfG:|aYOgRZN{e2G7 NWHuPJJuOi534pETN{42KG6P NWjGZVlFPDhiaB?= M3HSc4VvcGGwY3XzJJRp\SClZXzsJIRm[XSqIHPvMZRz\WG2bXXueEB4cXSqIFHDXVEzOTV? NEHzR2kzPTJ|OUmzOS=>
P-UMSCC-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjqbYRKSzVyPUGxMlIhdk1? M2fx[FI1QTF3MEO5
R-UMSCC-1 M1m4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojnTWM2OD1{Mkm0JI5O NXHjOYVQOjR7MUWwN|k>
P-Cal33 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF5LkOgcm0> NYrmelQ3OjR7MUWwN|k>
R-Cal33 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFixSnNKSzVyPUGxNVIhdk1? M2PyVVI1QTF3MEO5
Jurkat MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPtN3VFOS1zMX7N M3HzTVQ5KGh? NFnjc|ZqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHPvMZRz\WG2bXXueEB4cXSqII\vdolvd3O2YYS= M3iwfFI1QDBzMUK4
Jurkat NHHp[2FCeG:ydH;zbZMhSXO|c3H5 MojTPEBvVQ>? Ml;TNlQwPDhiaB?= M1HKbYlv\HWlZYOgZZBweHSxc3nzMEBk[XOyYYPlJIFkfGm4YYTpc44tKGGwZDDQRXJRKGOuZXH2ZYdmKGOxLYTy[YF1dWWwdDD3bZRpKH[xcnnuc5N1[XR? NGHycFQzPDhyMUGyPC=>
UMSCC-22A MmjRRZBweHSxc3nzJGF{e3OjeR?= MlflNlAxKG6P NGDLZ44zPCCq MYHpcoR2[2VidHjlJINmdGxiYYDvdJRwe2m|IHPvMZRz\WG2bXXueEB4cXSqIF;OXEAxQTF{ NELWSI0zOjl{OUiwNy=>
UMSCC-22B MX7BdI9xfG:|aYOgRZN{e2G7 MoLhNlAxKG6P MmfBNlQhcA>? NFWzdXlqdmS3Y3WgeIhmKGOnbHygZZBweHSxc3nzJINwNXS{ZXH0cYVvfCC5aYToJG9PYCByOUGy MWmyNlkzQThyMx?=
1483 M2\ZeWFxd3C2b4Ppd{BCe3O|YYm= NYP3fXZOOjByIH7N Ml\0NlQhcA>? MVzpcoR2[2VidHjlJINmdGxiYYDvdJRwe2m|IHPvMZRz\WG2bXXueEB4cXSqIF;OXEAxQTF{ MnraNlI6Ojl6MEO=
UMSCC-1 MWPBdI9xfG:|aYOgRZN{e2G7 MmfvNlAxKG6P M1rQXFI1KGh? NX3Ld3M{cW6mdXPlJJRp\SClZXzsJIFxd3C2b4Ppd{Bkdy22cnXheI1mdnRid3n0bEBQVlhiMEmxNi=> MVyyNlkzQThyMx?=
UMSCC-22A M2jDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX0NmtKSzVyPUO4MlchyrFiMT6wJI5O M{\4OlIzQTJ7OECz
UMSCC-22B NWDCd5dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHifWZKSzVyPUOwMlchyrFiOT6zJI5O NEjWT5AzOjl{OUiwNy=>
1483 M3TtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWwTWM2OD13MD61JOKyKDFzLkmgcm0> MWKyNlkzQThyMx?=
UMSCC-1 NHTqdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTMOVhXUUN3ME2zOE43KMLzIEKuOkBvVQ>? MVSyNlkzQThyMx?=
Cal33 NUDkRZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGSwWG5KSzVyPUS5MlMhyrFiOD65JI5O NGnrdXczOjl{OUiwNy=>
PCI-15A MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT5TlFEUUN3ME23NE41KMLzIEKyMlYhdk1? M3zNT|IzQTJ7OECz
PCI-15B NVH6TYxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\iTWM2OD1|OT61JOKyKDFzLkCgcm0> NFfWWJYzOjl{OUiwNy=>
OSC-19 NXO3PHlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXJTWM2OD1zOD6zJOKyKDRwMjDuUS=> M2jhSlIzQTJ7OECz
SUDHL16 NIDE[pVCeG:ydH;zbZMhSXO|c3H5 M1XYXFIvOC12LkCgcm0> MXO0PEBp M{flSolv\HWlZYOgZ4VtdCCmZXH0bEBkdy22cnXheI1mdnRid3n0bEBw[mG2b3PsZZg> M1fzTFIzPDFzOEm5
SUDHL16 MVPGeY5kfGmxbjDBd5NigQ>? M{XrcVIvPSCwTR?= M4\Q[lI1KGh? MYDhZ5RqfmG2ZYOgTm5MNCCrbnHjeIl3[XSnczDBT3QtKHWyLYLl[5Vt[XSnczDOc5hiNCCjbnSgbY5lfWOnczFOt2gzSS6[IHPvMZRz\WG2bXXueEB4cXSqIH;iZZRw[2yjeB?= NWXINFE2OjJ2MUG4PVk>
Granta NEnHb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[wMVQhdk1? M3ixU|Q5KGh? NV\ydFF4cW6mdXPlJINmdGxiZHXheIgh[29vdILlZZRu\W62IIfpeIghUEGGQ1nz NWfWOnN[OjF5NUCyNlQ>
SUDHL16 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOxMVQhdk1? NYOzSIJROzZiaB?= MXXpcoR2[2ViY3XscEBl\WG2aDDjc{11emWjdH3lcpQhf2m2aDDIRWREUXN? MorlNlAzOzN7N{O=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
pERK / ERK / pSTAT5 / STAT5 / pPI3K / PI3K; 

PubMed: 24590311     


Western blot analysis for activated (phosphorylated) ERK, Stat5 and PI3K signaling pathways following exposure to carfilzomib, total levels of ERK, Stat5 and PI3K were used as a loading control.

caspase-9 / caspase-8; 

PubMed: 24590311     


Western blot analysis for activated (cleaved) caspase-8 and caspase-9 following exposure to carfilzomib.

c-PARP / PARP / caspase-3; 

PubMed: 22929803     


UMSCC-22A, UMSCC-22B, 1483 and UMSCC-1 cells were treated for 24 hours with 0.1% DMSO, or 200 nmol/L carfilzomib or ONX 0912, followed by immunoblotting with anti-PARP, anti-caspase-3, or anti-β-actin. Shown are full-length PARP, cleaved PARP (c-PARP), and the cleaved, active subunits of caspase-3. Similar results were obtained in 3 independent experiments.

Bcl-2 / Bcl-Xl / Mcl-1 / Bik / Bim / Bax / Bak; 

PubMed: 22929803     


UMSCC-22A, UMSCC-22B, 1483 and UMSCC-1 cells were treated for 24 hours with 0.1% DMSO, or 100 nmol/L carfilzomib or ONX 0912, followed by immunoblotting for the indicated proteins. In the case of Bik immunoblotting, cells were treated with 200 nmol/L carfilzomib or ONX 0912 to more clearly demonstrate Bik upregulation in 1483 and UMSCC-1 cells. Blots shown are representative of 3 independent experiments. 

Atg5 / Atg12 / Beclin-1 / LC3-II; 

PubMed: 22929803     


HNSCC cells were treated for 24 hours with 100 nmol/L carfilzomib or ONX 0912, or with 0.1% DMSO. Immunoblots were probed for Beclin-1, Atg5/12 conjugate, LC3-II, or β-actin. Representative blots from 3 independent experiments are shown. 

Noxa / Bik / Puma / Mcl-1; 

PubMed: 25548100     


SW620 cells were treated with the indicated dosage for 48 h. Expression of Noxa, Bik and/or Puma, c-myc and Mcl-1 proteins was then analyzed by immunoblotting. Tubulin served as control for protein loading. 

EGFR / HER2 / ER alpha / p-Akt(Ser473) / Akt / p-ERK / ERK / p53; 

PubMed: 29069787     


T47D and MCF7 cells were cultured with the indicated carfilzomib concentrations for 32 or 36 hours, respectively. Western blots of protein lysates were probed with the indicated antibodies. β-actin served as loading control.

BDP1 / HER2(Tyr1248) / HER2(Tyr1221/Tyr1222) / PARP1 / caspase-7 / p53 Mut; 

PubMed: 29069787     


BT474 cells were cultured in the presence of the indicated carfilzomib concentrations for 32 hours. Western blots of protein lysates were probed with the indicated antibodies.

HLA class I; 

PubMed: 26323098     


Immunofluorescence analysis was performed to confirm the consequence that down-regulation of HLA class I was in a dose- and time-dependent manner.

24590311 22929803 25548100 29069787 26323098
Growth inhibition assay
Cell viability; 

PubMed: 27655642     


Cytotoxic effects of carfilzomib on breast cancer cells in MTT assays. Seven human breast cancer cell lines, MCF7, T-47D, MDA-MB-361, HCC1954, MDA-MB-468, MDA-MB-231, and BT-549 were treated with carfilzomib at 0, 0.001 μM, 0.01 μM, 0.05 μM, 0.1 μM, 1 μM, 10 μM, or 50 μM for 72 h, then subjected to MTT assays. The absorbance of each well was measured at 540 nm and plotted for the cell viability curve. IC50 values of carfilzomib in breast cancer cell lines were listed.

27655642
体内試験 Carfilzomib moderately reduces tumor growth in an in vivo xenograft model. Carfilzomib effectively decreases multiple myeloma cell viability following continual or transient treatment mimicking. Carfilzomib increases trabecular bone volume, decreases bone resorption and enhances bone formation in non-tumor bearing mice. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Enzyme-linked immunosorbent assay for subunit profiling of carfilzomib:

ANBL-6 cells (2 × 106/well) are plated in 96-well plates and treated with Carfilzomib doses from 0.001 to 10 μM for 1 hour. Cells are then lysed (20 mM Tris-HCl, 0.5 mM EDTA), and cleared lysates are transferred to polymerase chain reaction (PCR) plates. A standard curve is generated using untreated ANBL-6 cell lysates starting at a concentration of 6 μg protein/μL. The active site probe [biotin-(CH2)4-Leu-Leu-Leu-epoxyketone; 20 μM] is added and incubated at room temperature for 1 hour. Cell lysates are then denatured by adding 1% sodium dodecyl sulfate (SDS) and heating to 100°C, followed by mixing with 20 μL per well streptavidin-sepharose high-performance beads in a 96-well multiscreen DV plate and incubated for 1 hour. These beads are then washed with enzyme-linked immunosorbent assay (ELISA) buffer (PBS, 1% bovine serum albumin, and 0.1% Tween-20), and incubated overnight at 4°C on a plate shaker with antibodies to proteasome subunits. Antibodies used included mouse monoclonal anti-β1, anti-β2, anti-β1i, and anti-β5i, goat polyclonal anti-β2i, and rabbit polyclonal anti-β5 (affinity-purified antiserum against KLH-CWIRVSSDNVADLHDKYS peptide). The beads are washed and incubated for 2 hours with horseradish peroxidase-conjugated secondary goat antirabbit, goat antimouse or rabbit antigoat antibodies. After washing, the beads are developed using the supersignal ELISA picochemiluminescence substrate. Luminescent detection is performed. Raw luminescence is converted to μg/mL by comparison with the standard curve and expressed as the % inhibition relative to vehicle control. Curve fits are generated using the following nonsigmoidal dose-response equation: Y = Bottom + (Top-Bottom)/(1 + 10̂((LogEC50 − X) × HillSlope)), where X is the logarithm of concentration, Y is the % inhibition, and EC50 is the dose showing 50% effect.
細胞試験: [1]
+ 展開
  • 細胞株: WST-1, ANBL-6 cells
  • 濃度: 100 nM
  • 反応時間: 1 hour
  • 実験の流れ: WST-1 is used to determine the effects of proteasome inhibitor Carfilzomib on cell proliferation. The inhibition of proliferation is calculated in relation to parallel control cells that receives vehicle alone. A linear spline function is used to interpolate the median inhibitory concentration (IC50) using XLfit 4 software. The degree of resistance (DOR) is calculated using the formula: DOR = IC50(resistant cells)/IC50(sensitive cells). ANBL-6 cells pulsed with 100 nM carfilzomib are washed and suspended in PBS containing 5 μg/mL of JC-1, which exhibits potential-dependent accumulation in mitochondria. Analysis of the mitochondrial membrane potential-dependent color shift from 525 to 590 nm is carried out on a FacScan, and the data are analyzed with CellQuest software.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Beige-nude-XID mice
  • 製剤: 10% sulfobutylether β-cyclodextrin in 10 mmol/L citrate buffer pH 3.5,
  • 投薬量: 2.0 mg/kg
  • 投与方法: i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 50 mg/mL (69.45 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
1mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 719.91
化学式

C40H57N5O7

CAS No. 868540-17-4
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03795597 Not yet recruiting Multiple Myeloma Loyola University|Amgen February 1 2020 Phase 1|Phase 2
NCT03795597 Not yet recruiting Multiple Myeloma Loyola University|Amgen February 1 2020 Phase 1|Phase 2
NCT03871829 Not yet recruiting Multiple Myeloma Janssen Research & Development LLC May 31 2019 Phase 2
NCT03871829 Not yet recruiting Multiple Myeloma Janssen Research & Development LLC May 31 2019 Phase 2
NCT03859427 Not yet recruiting Relapsed or Refractory Multiple Myeloma Amgen April 23 2019 Phase 3
NCT03859427 Not yet recruiting Relapsed or Refractory Multiple Myeloma Amgen April 23 2019 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How should I prepare solution of Carfilzomib for ongoing in vivo study?

  • 回答:

    This compound can be dissolved in 2% DMSO/30% PEG 300/dd H2O at 10 mg/ml as a suspension, and can be dissolved in 2% DMSO/ castor oil at 10 mg/ml as a clear solution.

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: Carfilzomib (PR-171)を買う | Carfilzomib (PR-171) ic50 | Carfilzomib (PR-171)供給者 | Carfilzomib (PR-171)を購入する | Carfilzomib (PR-171)費用 | Carfilzomib (PR-171)生産者 | オーダーCarfilzomib (PR-171) | Carfilzomib (PR-171)化学構造 | Carfilzomib (PR-171)分子量 | Carfilzomib (PR-171)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID